AtriCure Ownership
| ATRC Stock | USD 33.40 0.35 1.04% |
Shares in Circulation | First Issued 2003-12-31 | Previous Quarter 47.1 M | Current Value 47.1 M | Avarage Shares Outstanding 26 M | Quarterly Volatility 14.1 M |
AtriCure Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The book value of AtriCure was presently reported as 9.43. The company recorded a loss per share of 0.95. AtriCure last dividend was issued on the 30th of September 2010. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Atricure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 875 people. For more info on AtriCure please contact Michael Carrel at 513 755 4100 or go to https://www.atricure.com.Besides selling stocks to institutional investors, AtriCure also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AtriCure's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AtriCure's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AtriCure Quarterly Liabilities And Stockholders Equity |
|
AtriCure Insider Trades History
Roughly 3.0% of AtriCure are currently held by insiders. Unlike AtriCure's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AtriCure's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AtriCure's insider trades
AtriCure Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AtriCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AtriCure backward and forwards among themselves. AtriCure's institutional investor refers to the entity that pools money to purchase AtriCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-12-31 | 981.5 K | Neuberger Berman Group Llc | 2024-12-31 | 939.2 K | Goldman Sachs Group Inc | 2024-12-31 | 853.7 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 811.4 K | Kennedy Capital Management Inc | 2024-12-31 | 752.6 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 700.2 K | Wellington Management Company Llp | 2024-12-31 | 654.5 K | Dafna Capital Management Llc | 2024-12-31 | 641.7 K | Two Sigma Advisers, Llc | 2024-12-31 | 639.4 K | Vanguard Group Inc | 2024-12-31 | 4.7 M | Blackrock Inc | 2024-12-31 | 4.3 M |
AtriCure Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AtriCure Outstanding Bonds
AtriCure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AtriCure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AtriCure bonds can be classified according to their maturity, which is the date when AtriCure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
AtriCure Corporate Filings
| 7th of April 2025 Other Reports | ViewVerify | |
8K | 26th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth 0.166 | Return On Assets | Return On Equity |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.